Brian M. Hahn - Jan 21, 2022 Form 4 Insider Report for GLYCOMIMETICS INC (GLYC)

Signature
/s/ Brian F. Leaf, attorney-in-fact
Stock symbol
GLYC
Transactions as of
Jan 21, 2022
Transactions value $
$0
Form type
4
Date filed
1/25/2022, 07:59 PM
Next filing
Mar 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLYC Employee Stock Option (right to buy) Award $0 +165K $0.00 165K Jan 21, 2022 Common Stock 165K $1.11 Direct F1
transaction GLYC Employee Stock Option (right to buy) Award $0 +47.7K $0.00 47.7K Jan 21, 2022 Common Stock 47.7K $1.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
F2 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.